LRRK2

News

Biogen has stopped development of Denali-partnered Parkinson's disease candidate BIIB122, after it failed to move the needle in a phase 2b trial.

R&D

The Parkinson's disease field is increasingly moving toward biologically defined disease frameworks using molecular biomarkers.

News

Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.